Exploring Easd 2017 Poster 815
Exploring Easd 2017 Poster 815 reveals several interesting facts.
- Vanita Aroda: Efficacy and safety of semaglutide in elderly subjects with type 2 diabetes: a post hoc analysis of the SUSTAIN 7 ...
- Guillermo Umpierrez Glycaemic efficacy and safety of linagliptin compared to basal bolus insulin regimen in non-cardiac surgical ...
- Kathleen Dungan More subjects achieved composite reductions of ≥1% HbA1c, ≥5% body weight and ≥5 mmHg SBP with ...
- Matthieu Raoux Real-time decoding of endogenous islet algorithms and their use in a type 1 diabetes simulator ...
- Manjiri Pawaskar Long-term cost-effectiveness of sitagliptin and SGLT2i combination therapy for the management of type 2 ...
In-Depth Information on Easd 2017 Poster 815
J. Hans DeVries More semaglutide-treated subjects achieved HbA1c below 7% without weight gain, hypoglycaemia, and ... John Buse 24-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 ... https://www. Liana Billings Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: ...
Mike Stedman Real world practice level data analysis confirms link between variability within blood glucose monitoring strip and ...
Stay tuned for more updates related to Easd 2017 Poster 815.